Strategies for cancer vaccine development

Journal of Biomedicine and Biotechnology

Volumn 2010, Issue , 2010, Pages

  Schlom, Jeffrey ^a   Vergati, Matteo ^a   Intrivici, Chiara ^a   Huen, Ngar Yee ^a   Tsang, Kwong Y ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VECTOR; CANCER VACCINE; CYCLOPHOSPHAMIDE; DNA VACCINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; LIPONOVA; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN PLUS TRIAD OF COSTIMULATORY MOLECULE; PROVENGE; RNA VACCINE; STIMUVAX; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR; VITESPEN;

ANTIGEN PRESENTING CELL; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; COLON CANCER; DRUG EFFICACY; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG CANCER; MELANOMA; NEPHRECTOMY; PANCREAS CANCER; PROSTATE CANCER; REVIEW; TUMOR IMMUNITY;

ANIMALS; BIOTECHNOLOGY; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 77955375829     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2010/596432     Document Type: Review

References (101)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M. J., Cancer statistics, 2009 CA Cancer Journal for Clinicians 2009 59 4 225 249
2. Kantoff P., Glode L., Tannenbaum S., Bilhartz D., Pittman W., Schuetz T., Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients (pts) with hormone-refractory prostate cancer (HRPC) [abstract] Journal of Clinical Oncology 2006 24 18S, abstract 2501
3. Kantoff P., Schuetz T., Blumenstein B., Overall survival (OS) analysis of a phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC) [abstract] Journal of Clinical Oncology 2009 27 15S, abstract 5013
4. Kantoff P., Schuetz T., Blumenstein B., Overall survival (OS) analysis of a phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology 2010 28 7 1099 1105
5. Halabi S., Small E. J., Kantoff P. W., Kattan M. W., Kaplan E. B., Dawson N. A., Levine E. G., Blumenstein B. A., Vogelzang N. J., Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer Journal of Clinical Oncology 2003 21 7 1232 1237
6. Goldman B., DeFrancesco L., The cancer vaccine roller coaster Nature Biotechnology 2009 27 2 129 139
7. Small E. J., Schellhammer P. F., Higano C. S., Redfern C. H., Nemunaitis J. J., Valone F. H., Verjee S. S., Jones L. A., Hershberg R. M., Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer Journal of Clinical Oncology 2006 24 19 3089 3094
8. Higano C. S., Schellhammer P. F., Small E. J., Burch P. A., Nemunaitis J., Yuh L., Provost N., Frohlich M. W., Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer Cancer 2009 115 16 3670 3679
9. Testori A., Richards J., Whitman E., Mann G. B., Lutzky J., Camacho L., Parmiani G., Tosti G., Kirkwood J. M., Hoos A., Yuh L., Gupta R., Srivastava P. K., Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 study group Journal of Clinical Oncology 2008 26 6 955 962
10. Wood C., Srivastava P., Bukowski R., Lacombe L., Gorelov A. I., Gorelov S., Mulders P., Zielinski H., Hoos A., Teofilovici F., Isakov L., Flanigan R., Figlin R., Gupta R., Escudier B., An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial The Lancet 2008 372 9633 145 154
11. Schwartzentruber D. J., Lawson D., Richards J., A phase III multi-institutional randomized study of immunization with the gp100:209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma Journal of Clinical Oncology 2009 27 18S, abstract CRA9011
12. Butts C., Murray N., Maksymiuk A., Goss G., Marshall E., Soulires D., Cormier Y., Ellis P., Price A., Sawhney R., Davis M., Mansi J., Smith C., Vergidis D., Ellis P., MacNeil M., Palmer M., Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer Journal of Clinical Oncology 2005 23 27 6674 6681
13. Vermorken J. B., Claessen A. M. E., van Tinteren H., Gall H. E., Ezinga R., Meijer S., Scheper R. J., Meijer C. J. L. M., Bloemena E., Ransom J. H., Hanna M. G. Jr., Pinedo H. M., Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial Lancet 1999 353 9150 345 350
14. Uyl-de Groot C. A., Vermorken J. B., Hanna M. G. Jr., Verboom P., Groot M. T., Bonsel G. J., Meijer C. J. L. M., Pinedo H. M., Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits Vaccine 2005 23 17-18 2379 2387
15. Hoover H. C. Jr., Surdyke M., Dangel R. B., Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Gúrin vaccine Cancer Research 1984 44 4 1671 1676
16. Jocham D., Richter A., Hoffmann L., Iwig K., Fahlenkamp D., Zakrzewski G., Schmitt E., Dannenberg T., Lehmacher W., Von Wietersheim J., Doehn C., Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial Lancet 2004 363 9409 594 599
17. Doehn C., Richter A., Theodor R., Lehmacher W., Jocham D., Prolongation of progression-free and overall survival following an adjuvant vaccination with Reniale in patients with non-metastatic renal cell carcinoma: secondary analysis of a multicenter phase-III trial [abstract] 395 Proceedings of the 27th German Cancer Congress Program and Abstracts 2006
18. Mu L. J., Kyte J. A., Kvalheim G., Aamdal S., Dueland S., Hauser M., Hammerstad H., Waehre H., Raabe N., Gaudernack G., Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients British Journal of Cancer 2005 93 7 749 756
19. Dougan M., Dranoff G., Immune therapy for cancer Annual Review of Immunology 2009 27 83 117
20. Palena C., Abrams S. I., Schlom J., Hodge J. W., Cancer vaccines: preclinical studies and novel strategies Advances in Cancer Research 2006 95 115 145
21. Bendle G. M., Holler A., Downs A.-M., Xue S.-A., Stauss H. J., Broadly expressed tumour-associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy Expert Opinion on Biological Therapy 2005 5 9 1183 1192
22. Schietinger A., Philip M., Schreiber H., Specificity in cancer immunotherapy Seminars in Immunology 2008 20 5 276 285
23. Emens L. A., Asquith J. M., Leatherman J. M., Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation Journal of Clinical Oncology 2009 27 35 5911 5918
24. Laheru D., Lutz E., Burke J., Biedrzycki B., Solt S., Onners B., Tartakovsky I., Nemunaitis J., Le D., Sugar E., Hege K., Jaffee E., Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation Clinical Cancer Research 2008 14 5 1455 1463
25. Garnett C. T., Schlom J., Hodge J. W., Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement Clinical Cancer Research 2008 14 11 3536 3544
26. Lutsiak M. E. C., Semnani R. T., De Pascalis R., Kashmiri S. V. S., Schlom J., Sabzevari H., Inhibition of CD 4 + 25 + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide Blood 2005 105 7 2862 2868
27. Lechleider R. J., Arlen P. M., Tsang K.-Y., Steinberg S. M., Yokokawa J., Cereda V., Camphausen K., Schlom J., Dahut W. L., Gulley J. L., Safety and immunologic response of a viral vaccine to prostate- specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant Clinical Cancer Research 2008 14 16 5284 5291
28. Kantor J., Abrams S., Irvine K., Snoy P., Kaufman H., Schlom J., Specific immunotherapy using a recombinant vaccinia virus expressing human carcinoembryonic antigen Annals of the New York Academy of Sciences 1993 690 370 373
29. Kass E., Schlom J., Thompson J., Guadagni F., Graziano P., Greiner J. W., Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus Cancer Research 1999 59 3 676 683
30. Acres B., Bonnefoy J.-Y., Clinical development of MVA-based therapeutic cancer vaccines Expert Review of Vaccines 2008 7 7 889 893
31. Taylor J., Paoletti E., Fowlpox virus as a vector in a non-avian species Vaccine 1988 6 6 466 468
32. Stickl H., Hochstein-Mintzel V., Mayr A., Huber H. C., Schfer H., Holzner A., MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl) Deutsche Medizinische Wochenschrift 1974 99 47 2386 2392
33. Hodge J. W., McLaughlin J. P., Kantor J. A., Schlom J., Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses Vaccine 1997 15 6-7 759 768
34. Grosenbach D. W., Barrientos J. C., Schlom J., Hodge J. W., Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects Cancer Research 2001 61 11 4497 4505
35. Slack R., Ley L., Chang P., Association between CEA-specific T cell responses (TCR) following treatment with vaccinia-CEA (V) and Alvac-CEA (A) and survival in patients with CEA-bearing cancers [abstract] WProceedings of the American Society of Clinical Oncology 2001 20 1086
36. Kaufman H. L., Wang W., Manola J., Dipaola R. S., Ko Y.-J., Sweeney C., Whiteside T. L., Schlom J., Wilding G., Weiner L. M., Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group Journal of Clinical Oncology 2004 22 11 2122 2132
37. Hodge J. W., Schlom J., Costimulatory molecules in vaccine design Ernst Schering Research Foundation Workshop 2000 30 23 52
38. Terasawa H., Tsang K.-Y., Gulley J., Arlen P., Schlom J., Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen Clinical Cancer Research 2002 8 1 41 53
39. Gulley J., Chen A. P., Dahut W., Arlen P. M., Bastian A., Steinberg S. M., Tsang K., Panicali D., Poole D., Schlom J., Hamilton J. M., Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer Prostate 2002 53 2 109 117
40. Gulley J. L., Arlen P. M., Madan R. A., Tsang K.-Y., Pazdur M. P., Skarupa L., Jones J. L., Poole D. J., Higgins J. P., Hodge J. W., Cereda V., Vergati M., Steinberg S. M., Halabi S., Jones E., Chen C., Parnes H., Wright J. J., Dahut W. L., Schlom J., Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer Cancer Immunology, Immunotherapy 2010 59 5 1 12
41. Zaremba S., Barzaga E., Zhu M., Soares N., Tsang K.-Y., Schlom J., Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen Cancer Research 1997 57 20 4570 4577
42. Tsang K.-Y., Palena C., Gulley J., Arlen P., Schlom J., A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1 Clinical Cancer Research 2004 10 6 2139 2149
43. Gulley J. L., Arlen P. M., Tsang K.-Y., Yokokawa J., Palena C., Poole D. J., Remondo C., Cereda V., Jones J. L., Pazdur M. P., Higgins J. P., Hodge J. W., Steinberg S. M., Kotz H., Dahut W. L., Schlom J., Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma Clinical Cancer Research 2008 14 10 3060 3069
44. Trinchieri G., Sher A., Cooperation of Toll-like receptor signals in innate immune defence Nature Reviews Immunology 2007 7 3 179 190
45. Brockstedt D. G., Dubensky T. W. Jr., Promises and challenges for the development of Listeria monocytogenes-based immunotherapies Expert Review of Vaccines 2008 7 7 1069 1084
46. Franzusoff A., Duke R. C., King T. H., Lu Y., Rodell T. C., Yeasts encoding tumour antigens in cancer immunotherapy Expert Opinion on Biological Therapy 2005 5 4 565 575
47. Bolhassani A., Rafati S., Heat-shock proteins as powerful weapons in vaccine development Expert Review of Vaccines 2008 7 8 1185 1199
48. Cereda V., Poole D. J., Palena C., Das S., Bera T. K., Remondo C., Gulley J. L., Arlen P. M., Yokokawa J., Pastan I., Schlom J., Tsang K. Y., New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy Cancer Immunology, Immunotherapy 2010 59 1 63 71
49. Palena C., Polev D. E., Tsang K. Y., Fernando R. I., Litzinger M., Krukovskaya L. L., Baranova A. V., Kozlov A. P., Schlom J., The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cellmediated cancer immunotherapy Clinical Cancer Research 2007 13 8 2471 2478
50. Yokokawa J., Bera T. K., Palena C., Cereda V., Remondo C., Gulley J. L., Arlen P. M., Pastan I., Schlom J., Tsang K. Y., Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4) International Journal of Cancer 2007 121 3 595 605
51. + T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients Journal of Experimental Medicine 2004 200 3 297 306
52. Ai W. Z., Tibshirani R., Taidi B., Czerwinski D., Levy R., Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma Blood 2009 113 23 5743 5746
53. Hernndez A. M., Toledo D., Martnez D., Grin T., Brito V., Macas A., Alfonso S., Rondn T., Surez E., Vzquez A. M., Prez R., Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody Journal of Immunology 2008 181 9 6625 6634
54. So-Rosillo R., Small E. J., Sipuleucel-T (APC8015) for prostate cancer Expert Review of Anticancer Therapy 2006 6 9 1163 1167
55. Ostrand-Rosenberg S., Immune surveillance: a balance between protumor and antitumor immunity Current Opinion in Genetics and Development 2008 18 1 11 18
56. Kalinski P., Urban J., Narang R., Berk E., Wieckowski E., Muthuswamy R., Dendritic cell-based therapeutic cancer vaccines: what we have and what we need Future Oncology 2009 5 3 379 390
57. Cerundolo V., Hermans I. F., Salio M., Dendritic cells: a journey from laboratory to clinic Nature Immunology 2004 5 1 7 10
58. Lesterhuis W. J., de Vries I. J. M., Adema G. J., Punt C. J. A., Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results Annals of Oncology 2004 15 supplement 4 iv145 iv151
59. Yokokawa J., Palena C., Arlen P., Hassan R., Ho M., Pastan I., Schlom J., Tsang K. Y., Identification of novel human CTL epitopes and their agonist epitopes of mesothelin Clinical Cancer Research 2005 11 17 6342 6351
60. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van Den Eynde B., Knuth A., Boon T., A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma Science 1991 254 5038 1643 1647
61. Kessler J. H., Melief C. J. M., Identification of T-cell epitopes for cancer immunotherapy Leukemia 2007 21 9 1859 1874
62. Campoli M., Ferrone S., HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance Oncogene 2008 27 45 5869 5885
63. Butts C. M., Maksymiuk A., Goss G., A multicentre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis: B101 [abstract] Journal of Thoracic Oncology 2007 2 S332 S333
64. Copier J., Dalgleish A., Overview of tumor cell-based vaccines International Reviews of Immunology 2006 25 5-6 297 319
65. + T cells Nature Immunology 2006 7 5 475 481
66. + T lymphocytes Nature 2003 421 6925 852 856
67. Simmons A. D., Li B., Gonzalez-Edick M., Lin C., Moskalenko M., Du T., Creson J., VanRoey M. J., Jooss K., GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action Cancer Immunology, Immunotherapy 2007 56 10 1653 1665
68. Simons J. W., Carducci M. A., Mikhak B., Lim M., Biedrzycki B., Borellini F., Clift S. M., Hege K. M., Ando D. G., Piantadosi S., Mulligan R., Nelson W. G., Phase I/II trial of an allogeneic cellular immunotherapy in hormone-nave prostate cancer Clinical Cancer Research 2006 12 11, part 1 3394 3401
69. Small E. J., Sacks N., Nemunaitis J., Urba W. J., Dula E., Centeno A. S., Nelson W. G., Ando D., Howard C., Borellini F., Nguyen M., Hege K., Simons J. W., Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer Clinical Cancer Research 2007 13 13 3883 3891
70. Higano C. S., Corman J. M., Smith D. C., Centeno A. S., Steidle C. P., Gittleman M., Simons J. W., Sacks N., Aimi J., Small E. J., Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer Cancer 2008 113 5 975 984
71. Hodi F. S., Butler M., Oble D. A., Seiden M. V., Haluska F. G., Kruse A., MacRae S., Nelson M., Canning C., Lowy I., Korman A., Lautz D., Russell S., Jaklitsch M. T., Ramaiya N., Chen T. C., Neuberg D., Allison J. P., Mihm M. C., Dranoff G., Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients Proceedings of the National Academy of Sciences of the United States of America 2008 105 8 3005 3010
72. Best S. R., Peng S., Juang C.-M., Hung C.-F., Hannaman D., Saunders J. R., Wu T.-C., Pai S. I., Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery Vaccine 2009 27 40 5450 5459
73. U'Ren L., Kedl R., Dow S. W., Vaccination with liposome-DNA complexes elicits enhanced antitumor immunity Cancer Gene Therapy 2006 13 11 1033 1044
74. Pasquini S., Xiang Z., Wang Y., He Z., Deng H., Blaszczyk-Thurin M., Ertl H. C. J., Cytokines and costimulatory molecules as genetic adjuvants Immunology and Cell Biology 1997 75 4 397 401
75. Conry R. M., Curiel D. T., Strong T. V., Moore S. E., Allen K. O., Barlow D. L., Shaw D. R., LoBuglio A. F., Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients Clinical Cancer Research 2002 8 9 2782 2787
76. + T cells Nature Immunology 2005 6 6 593 599
77. Segal B. H., Wang X.-Y., Dennis C. G., Youn R., Repasky E. A., Manjili M. H., Subjeck J. R., Heat shock proteins as vaccine adjuvants in infections and cancer Drug Discovery Today 2006 11 11-12 534 540
78. Pavlenko M., Roos A.-K., Lundqvist A., Palmborg A., Miller A. M., Ozenci V., Bergman B., Egevad L., Hellstrm M., Kiessling R., Masucci G., Wersll P., Nilsson S., Pisa P., A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer British Journal of Cancer 2004 91 4 688 694
79. McNeel D. G., Dunphy E. J., Davies J. G., Frye T. P., Johnson L. E., Staab M. J., Horvath D. L., Straus J., Alberti D., Marnocha R., Liu G., Eickhoff J. C., Wilding G., Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer Journal of Clinical Oncology 2009 27 25 4047 4054
80. Yuan J., Ku G. Y., Gallardo H. F., Orlandi F., Manukian G., Rasalan T. S., Xu Y., Li H., Vyas S., Mu Z., Chapman P. B., Krown S. E., Panageas K., Terzulli S. L., Old L. J., Houghton A. N., Wolchok J. D., Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma Cancer Immunity 2009 9 5
81. Cassaday R. D., Sondel P. M., King D. M., Macklin M. D., Gan J., Warner T. F., Zuleger C. L., Bridges A. J., Schalch H. G., Kyung M. K., Hank J. A., Mahvi D. M., Albertini M. R., A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients Clinical Cancer Research 2007 13 2 540 549
82. Michaluart P., Abdallah K. A., Lima F. D., Smith R., Moyss R. A., Coelho V., Victora G. D., Socorro-Silva A., Volsi E. C., Zrate-Blads C. R., Ferraz A. R., Barreto A. K., Chammas M. C., Gomes R., Gebrim E., Arakawa-Sugueno L., Fernandes K. P., Lotufo P. A., Cardoso M. R., Kalil J., Silva C. L., Phase I trial of DNA-hsp65 immunotherapy for advanced squamous cell carcinoma of the head and neck Cancer Gene Therapy 2008 15 10 676 684
83. Kyte J. A., Gaudernack G., Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells Cancer Immunology, Immunotherapy 2006 55 11 1432 1442
84. Weide B., Garbe C., Rammensee H.-G., Pascolo S., Plasmid DNA- and messenger RNA-based anti-cancer vaccination Immunology Letters 2008 115 1 33 42
85. Yamamoto A., Kormann M., Rosenecker J., Rudolph C., Current prospects for mRNA gene delivery European Journal of Pharmaceutics and Biopharmaceutics 2009 71 3 484 489
86. Van Tendeloo V. F. I., Ponsaerts P., Lardon F., Nijs G., Lenjou M., Van Broeckhoven C., Van Bockstaele D. R., Berneman Z. N., Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells Blood 2001 98 1 49 56
87. Ponsaerts P., van der Sar S., Van Tendeloo V. F. I., Jorens P. G., Berneman Z. N., Singh P. B., Highly efficient mRNA-based gene transfer in feeder-free cultured H9 human embryonic stem cells Cloning and Stem Cells 2004 6 3 211 216
88. Krieg P. A., Melton D. A., Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs Nucleic Acids Research 1984 12 18 7057 7070
89. Heiser A., Coleman D., Dannull J., Yancey D., Maurice M. A., Lallas C. D., Dahm P., Niedzwiecki D., Gilboa E., Vieweg J., Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors Journal of Clinical Investigation 2002 109 3 409 417
90. Morse M. A., Nair S. K., Mosca P. J., Hobeika A. C., Clay T. M., Deng Y., Boczkowski D., Proia A., Neidzwiecki D., Clavien P.-A., Hurwitz H. I., Schlom J., Gilboa E., Lyerly H. K., Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA Cancer Investigation 2003 21 3 341 349
91. Hirschowitz E. A., Foody T., Kryscio R., Dickson L., Sturgill J., Yannelli J., Autologous dendritic cell vaccines for non-small-cell lung cancer Journal of Clinical Oncology 2004 22 14 2808 2815
92. Pandha H. S., John R. J., Hutchinson J., James N., Whelan M., Corbishley C., Dalgleish A. G., Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells a phase I/II study BJU International 2004 94 3 412 418
93. Kyte J. A., Kvalheim G., Aamdal S., Sbe-Larssen S., Gaudernack G., Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination Cancer Gene Therapy 2005 12 6 579 591
94. Pascolo S., Messenger RNA-based vaccines Expert Opinion on Biological Therapy 2004 4 8 1285 1294
95. + T cell responses in patients with metastatic prostate cancer Journal of Immunology 2005 174 6 3798 3807
96. Su Z., Dannull J., Heiser A., Yancey D., Pruitt S., Madden J., Coleman D., Niedzwiecki D., Gilboa E., Vieweg J., Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells Cancer Research 2003 63 9 2127 2133
97. Dannull J., Su Z., Rizzieri D., Yang B. K., Coleman D., Yancey D., Zhang A., Dahm P., Chao N., Gilboa E., Vieweg J., Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells Journal of Clinical Investigation 2005 115 12 3623 3633
98. Caruso D. A., Orme L. M., Neale A. M., Radcliff F. J., Armor G. M., Maixner W., Downie P., Hassall T. E., Tang M. L. K., Ashley D. M., Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer Neuro-Oncology 2004 6 3 236 246
99. Caruso D. A., Orme L. M., Amor G. M., Neale A. M., Radcliff F. J., Downie P., Tang M. L. K., Ashley D. M., Results of a phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with stage 4 neuroblastoma Cancer 2005 103 6 1280 1291
100. Kyte J. A., Mu L., Aamdal S., Kvalheim G., Dueland S., Hauser M., Gullestad H. P., Ryder T., Lislerud K., Hammerstad H., Gaudernack G., Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA Cancer Gene Therapy 2006 13 10 905 918
101. Weide B., Pascolo S., Scheel B., Derhovanessian E., Pflugfelder A., Eigentler T. K., Pawelec G., Hoerr I., Rammensee H.-G., Garbe C., Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients Journal of Immunotherapy 2009 32 5 498 507